1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi.
The transaction amount is as high as 1.1 billion US dollars! Regeneron buys cancer drug from Sanofi.
Recently, Regeneron agreed to purchase the immuno-oncology drug Libtayo (simipritimab) from its partner Sanofi in a transaction amounting to US$1.1 billion.
The transaction is a continuation of the global immuno-oncology licensing and collaboration agreement signed by the two parties in 2015.
Before the transaction, the two parties shared Libtayo’s global sales profits and jointly commercialized Libtayo in the United States, while Sanofi was solely responsible for the commercialization of the rest of the world.
Under the agreement, Sanofi will transfer all rights to Libtayo (including the rights to develop, commercialize and manufacture it worldwide) to Regeneron, which will receive the exclusive worldwide license to Libtayo.
Sanofi will receive an up-front payment of $900 million, followed by milestone payments of $200 million once the drug hits certain regulatory and sales targets. In addition, Sanofi will receive an 11% royalty fee on Libtayo’s net profit from global sales.
Libtayo is a prescription drug used to treat cutaneous squamous cell carcinoma (CSCC), locally advanced basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC).
According to Regeneron’s previously released financial results for the fourth quarter and full year of 2021, Libtayo has brought the company approximately $306 million in net product sales for the full year of 2021.
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
(source:internet, reference only)
Disclaimer of medicaltrend.org
